Asthma: Why Pharmacogenomics Cannot Deliver a Decisive Prognosis

In its “multifactorialness, asthma, as a condition, has continued to see a marked increase in prevalence. Even though this may be tied to the population explosion that is witnessed in the world, the multifactorial nature of the condition makes it an ever-present issue in the world today. The condition’s prognosis is not tied to how very developed a certain country is; as such, it is necessary to approach it as a global phenomenon affecting all and sundry. This, therefore, requires an increase in the research into its existential prevalence. Health research foray into pharmacogenomics has shown great promise in tackling many genetically induced medical conditions. Thus, even though the process is financially demanding, its promise should not be downplayed. The simple question that this inquiry seeks to underscore is, why is pharmacogenomics stunted in dealing decisively with the asthmatic condition in individuals, ergo ensuring that we still have this as an issue? We might say that it is because it is multi-factorial, a combination of genetic and environmental factors. However, this clause is not as simple as it presents itself. Therefore, the inquiry still stands. This research seeks to bring to the fore the most recent advancement in that which pertains to the asthmatic condition, including the pharmacological breakthroughs that have been witnessed. However, the above-stated inquiry as to pharmacogenomics and its failure in dealing decisively with the asthmatic condition remains.